Table 2: Univariate median survival estimates (months) and hazard ratios.
Median Survival | Hazard Ratio | ||||
N | 95% CI | Estimate | 95% CI | P-Value | |
Age at diagnosis | |||||
< 40* 40-59 60-79 80+ |
242 687 543 123 |
Incalculable*** 248 ± 33.80 122 ± 12.80 58 ± 10.87 |
Reference 1.69 3.62 9.78 |
1.24-2.34 2.67-5.00 6.59-14.70 |
< 0.001 < 0.001 < 0.001 |
Race | |||||
White* Black Asian/Pacific Islanders Other/Unknown |
1229 153 189 24 |
181 ± 18.98 205 ± 66.57 132 ± 39.85 184 ± 60.41 |
Reference 0.99 1.28 1.37 |
0.75-1.30 0.99-1.64 0.62-2.63 |
0.999 0.055 0.323 |
Gender | |||||
Female* Male |
952 643 |
198 ± 22.57 147 ± 21.58 |
Reference 1.24 |
1.06-1.46 |
0.008 |
Received Radiation | |||||
Yes* No Unknown |
1116 454 25 |
173 ± 19.66 188 ± 35.50 Incalculable*** |
Reference 0.95 0.71 |
0.79-1.13 0.28-1.47 |
0.571 0.515 |
Surgery | |||||
Yes* No Unknown |
535 62 998 |
194 ± 24.11 71 ± 12.02 206 ± 72.13 |
Reference 2.72 1.09 |
2.00-3.65 0.91-1.31 |
< 0.001 0.343 |
Surgery Type | |||||
Gross* Partial None Other/Unknown |
383 148 62 1002 |
194 ± 32.50 197 ± 34.51 71 ± 12.02 181 ± 38.73 |
Reference 0.92 2.63 1.05 |
0.71-1.20 1.91-3.56 0.86-1.28 |
0.566 < 0.001 0.625 |
Lymph Node Involvement | |||||
Yes* No Unknown |
392 1194 9 |
111 22.76 203 22.31 38 2.44 |
Reference 0.56 2.69 |
0.48-0.66 1.05-5.75 |
< 0.001 0.020 |
Tumor Size (mms in largest dimension) | |||||
< 21* 21-40 > 40 Unknown |
599 586 181 229 |
260 ± 28.53 143 ± 21.06 89 ± 14.45 148 ± 24.74 |
Reference 1.85 3.29 1.85 |
1.52-2.26 2.54-4.25 1.46-2.36 |
< 0.001 < 0.001 < 0.001 |
Tumor Site | |||||
Major Salivary Glands* Palate Unspecified Mouth Parts Tongue Mouth Floor Nasopharynx Lip Other |
935 266 111 108 43 53 49 30 |
203 ± 32.92 184 ± 34.73 197 ± 67.11 10.3 ± 29.11 139 ± 63.86 59 ± 19.34 173 ± 51.55 129 ± 157.19 |
Reference 1.08 0.97 1.81 1.57 3.13 1.13 1.73 |
0.86-1.35 0.69-1.34 1.36-2.40 0.97-2.42 2.16-4.40 0.69-1.76 0.78-3.34 |
0.466 0.936 < 0.001 0.056 < 0.001 0.552 0.116 |
*Reference group against which other groups' survival experience are compared; **P value for log-rank testing the null hypothesis that the groups' survival experience is same as reference group; ***Median includable as more than 50% survived by end of study.